Characteristics of AEEA-AEEA

ADC aggregation and rapid clearance are the main obstacles leading to high immunogenicity, low efficacy, and batch failure. Introducing hydrophilic linkers (containing PEG units such as AEEA-AEEA) is an effective strategy to address these two issues.
The mechanism for reducing aggregation: The driving force for ADC aggregation is mainly the mutual attraction between hydrophobic drug molecules. When DAR>4, multiple drug molecules concentrate on the surface of the antibody, forming a "hydrophobic plaque". Hydrophilic PEG linkers (such as AEEA-AEEA) prevent aggregation through the following methods: ① hydration layer repulsion: PEG chains bind a large number of water molecules, and each EO unit binds 2-3 H ₂ O, forming a hydration layer with a thickness of about 0.5-1 nm/unit. The total thickness of the hydration layer contributed by two AEEA units and four EO is about 2 nm, which is sufficient to form an effective barrier between drug molecules. The repulsive energy is about 3-5 kT, far greater than the hydrophobic attraction of 1-2 kT. ② Conformational entropy repulsion: The flexible conformation of PEG chains reduces their entropy when compressed, generating entropy elastic repulsion and further resisting aggregation. The experiment showed that using AEEA-AEEA ADC (DAR=6) at a concentration of 5 mg/mL, the aggregation rate (SEC-HPLC detection of HMW aggregates) was less than 3%; The control without PEG linker (DAR=4) had aggregates>15%.
The mechanism of delaying clearance: clearance receptors on Kupffer cells and sinusoidal endothelial cells in the liver, such as scavenger receptor SR-B1 and mannose receptor MR recognition antibody specific domains. Hydrophobic drug loading on the surface of antibodies exposes hydrophobic regions, enhancing the affinity for clearing receptors. The hydrophilic PEG chains of AEEA-AEEA can effectively 'mask' these hydrophobic regions. Research has shown that ADC using PEG linkers reduces liver uptake by 50-60% compared to the non PEG control group, and plasma clearance rate decreases from 12 mL/h/kg to 6 mL/h/kg. The half-life of the cycle was extended from 3 days to 7 days in a mouse model. In addition, hydrophilicity also reduces the risk of binding to anti PEG antibodies (when PEG length is moderate, the immunogenicity of AEEA dimer is much lower than that of long-chain PEG such as PEG2000).
Formula synergy: Hydrophilic linkers also simplify formulation development - maintaining stability without the need for high concentrations of surfactants. In freeze-dried formulations, the aggregation of ADC containing AEEA-AEEA after reconstitution is less than 1%, far exceeding the pharmacopoeia standard (<5%). Therefore, hydrophilic PEG linkers have become a "standard" design element for ADC stability and long cycling.